The global human growth hormone market size was valued at USD 6.81 billion in 2024 and is projected to reach from USD 7.63 billion in 2025 to USD 18.75 billion by 2033, growing at a CAGR of 11.90% ...

With over two decades in breast cancer research and patient support, Pfizer believes ... especially for patients with hormone receptor-positive (HR +)/human epidermal growth factor receptor ...

Levi Garraway, Roche’s chief medical officer and head of global product development, said: “The INAVO120 overall survival ...

Pfizer is to make its breast cancer ... in first line for hormone receptor positive, human epidermal growth factor receptor 2 negative, locally advanced or metastatic breast cancer.

Pfizer’s Ibrance breast cancer ... an aromatase inhibitor in first-line treatment of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced ...